trial

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

NCTId NCT02970305
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 403 (actual)
Sponsored by ACADIA Pharmaceuticals Inc.
Primary completion 2019-10-16
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
403 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-11-04
Primary completion
2019-10-16
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Pimavanserin

Sponsors

ACADIA Pharmaceuticals Inc.Lead Sponsor

Sites

0 total

Linked catalysts

1
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Sym — primary completion2019-10-16

Facts & assertions

4 sourced
Enrollment
403
Phase
PHASE2
Primary Completion Date
2019-10-16
Status
COMPLETED
relationships
The graph out of here
drug
Pimavanserin
drug
lead_sponsor
ACADIA Pharmaceuticals Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication